CYTOPOINT™ gives damaged skin a chance to heal after 1 injection1
*Treatment success was defined as a ≥50% reduction from baseline in skin condition scores as assessed by veterinarians using the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) score. CADESI-03 skin condition assessment consisted of an evaluation of erythema, lichenification, excoriation and self-induced alopecia at 62 body sites.1
†Significantly different compared to placebo (P≤0.05).
Indication: CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs.
Reference: 1. Data on file, Study Report No. C863R-US-12-018, Zoetis LLC.
The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. Zoetis Services LLC. All rights reserved. CYT-00090